Long-term safety of drug-eluting and bare-metal stents: Evidence from a comprehensive network meta-analysis

Journal of the American College of Cardiology

Volumn 65, Issue 23, 2015, Pages 2496-2507

  Palmerini, Tullio ^a   Benedetto, Umberto ^b   Biondi Zoccai, Giuseppe ^c   Della Riva, Diego ^a   Bacchi Reggiani, Letizia ^a   Smits, Pieter C ^d   Vlachojannis, Georgios J ^d   Jensen, Lisette Okkels ^e   Christiansen, Evald H ^f   Berencsi, Klára ^e   Valgimigli, Marco ^g   Orlandi, Carlotta ^a   Petrou, Mario ^b   Rapezzi, Claudio ^a   Stone, Gregg W ^h  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Maasstad Hospital Rotterdam   (Netherlands)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h NewYork Presbyterian Hospital   (United States)

Author keywords

bare metal stent(s); drug eluting stent(s); meta analysis; stent thrombosis

Indexed keywords

COBALT CHROMIUM; COBALT DERIVATIVE; EVEROLIMUS; PACLITAXEL; PHOSPHORYLCHOLINE; RAPAMYCIN; UNCLASSIFIED DRUG; ZOTAROLIMUS; METAL;

ARTICLE; BARE METAL STENT; BIOLIMUS ELUTING CORONARY STENT; DEVICE SAFETY; DRUG ELUTING STENT; EVEROLIMUS ELUTING CORONARY STENT; EVIDENCE BASED MEDICINE; FOLLOW UP; HEART INFARCTION; HUMAN; LONG TERM CARE; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PACLITAXEL ELUTING CORONARY STENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; SIROLIMUS ELUTING CORONARY STENT; STENT THROMBOSIS; ZOTAROLIMUS ELUTING CORONARY STENT; ADVERSE EFFECTS; DEVICES; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; STENT; THROMBOSIS; TIME; TREATMENT OUTCOME; TRENDS;

DRUG-ELUTING STENTS; FOLLOW-UP STUDIES; HUMANS; METALS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STENTS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84930691483     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.04.017     Document Type: Article

References (42)

1. J.W. Moses, M.B. Leon, J.J. Popma for the SIRIUS Investigators Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 349 2003 1315 1323
2. G.W. Stone, S.G. Ellis, L. Cannon for the TAXUS V Investigators Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial JAMA 294 2005 1215 1223
3. E. Camenzind, P.G. Steg, and W. Wijns Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern Circulation 115 2007 1440 1455
4. T. Palmerini, G. Biondi-Zoccai, and D. Della Riva Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis Lancet 379 2012 1393 1402
5. M. Sabate, A. Cequier, and A. Iñiguez Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial Lancet 380 2012 1482 1490
6. E. Camenzind, W. Wijns, L. Mauri for the PROTECT Steering Committee and Investigators Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial Lancet 380 2012 1396 1405
7. T. Palmerini, G. Biondi-Zoccai, and D. Della Riva Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis J Am Coll Cardiol 63 2014 299 307
8. S.J. Brener, D.J. Kereiakes, and C.A. Simonton Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial Am Heart J 166 2013 1035 1042
9. Christiansen EH, Jensen LO, Thayssen P, et al. Biolimus-eluting biodegradable polymer-coated stent versus a durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention. SORT-OUT V: 3-year outcome. Lecture presented at: EuroPCR; May 21, 2014; Paris, France.
10. E. Di Lorenzo, R. Sauro, and A. Varricchio Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial J Am Coll Cardiol Intv 7 2014 849 856
11. H. Gada, A.J. Kirtane, and W. Newman 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions) J Am Coll Cardiol Intv 6 2013 1263 1266
12. L.O. Jensen, P. Thayssen, and E.H. Christiansen Improved Safety and Reduction in Stent Thrombosis after Everolimus-Eluting Stents versus Sirolimus-Eluting Stents in Patients with Coronary Artery Disease: SORT OUT IV 5-Year (abstr) J Am Coll Cardiol 64 Suppl 2014 B186 B187
13. A.J. Kirtane, M.B. Leon, M.W. Ball for the ENDEAVOR IV Investigators The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent J Am Coll Cardiol Intv 6 2013 325 333
14. M. Maeng, H.H. Tilsted, and L.O. Jensen Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial Lancet 383 2014 2047 2056
15. Y. Onuma, K. Miquel-Hebert, P.W. Serruys for the SPIRIT II Investigators Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: the SPIRIT II trial EuroIntervention 8 2013 1047 1051
16. P. Smits, K. Sheikjoesoef, and K. Royaards Final five year results from the all-comer COMPARE trial: a prospective, randomized trial of everolimus-eluting vs. paclitaxel-eluting stents (abstr) J Am Coll Cardiol 62 Suppl 1 2013 B5 http://dx.doi.org/10.1016/j.jacc.2013.08.741
17. G.J. Vlachojannis, P.C. Smits, and S.H. Hofma Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: 3 year follow-up from the COMPARE II trial (abstr) J Am Coll Cardiol 64 Suppl 2014 B5
18. M. Taniwaki, G.G. Stefanini, S. Silber on behalf of the RESOLUTE All-Comers Investigators 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention) J Am Coll Cardiol 63 2014 1617 1625
19. M. Tebaldi, C. Arcozzi, G. Campo, G. Percoco, R. Ferrari, M. Valgimigli for the STRATEGY Investigators The 5-year clinical outcomes after a randomized comparison of sirolimus-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction J Am Coll Cardiol 54 2009 1900 1901
20. W. Wijns, P.G. Steg, and L. Mauri Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent: 4-year results of the PROTECT randomized trial Eur Heart J 35 2014 2812 2820
21. D.E. Cutlip, S. Windecker, R. Mehran on behalf of the Academic Research Consortium Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
22. B. Chevalier, P.W. Serruys, and S. Silber Randomised comparison of Nobori, biolimus A9-eluting coronary stent with a Taxus, paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial EuroIntervention 2 2007 426 434
23. B. Chevalier, S. Silber, S.J. Park for the NOBORI 1 Clinical Investigators Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial-Phase 2 Circ Cardiovasc Interv 2 2009 188 195
24. E.H. Christiansen, L.O. Jensen, P. Thayssen for the Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) V Investigators Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial [published correction appears in Lancet 2013;382:310] Lancet 381 2013 661 669
25. P.C. Smits, S. Hofma, and M. Togni Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial Lancet 381 2013 651 660
26. S. Windecker, P.W. Serruys, and S. Wandel Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial Lancet 372 2008 1163 1173
27. S. Gillen, T. Schuster, C. Meyer Zum Buschenfelde, H. Friess, and J. Kleeff Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages PLoS Med 7 2010 e1000267
28. T. Palmerini, A.J. Kirtane, P.W. Serruys for the SPIRIT IV Investigators Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials Circ Cardiovasc Interv 5 2012 357 364
29. G.W. Stone, A. Rizvi, W. Newman for the SPIRIT IV Investigators Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease N Engl J Med 362 2010 1663 1674
30. S. Bangalore, S. Kumar, and M. Fusaro Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials Circulation 125 2012 2873 2891
31. S.H. Kang, K.W. Park, D.Y. Kang for the ENDEAVOR III Investigators Biodegradable-polymer drug-eluting stents vs. Bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis Eur Heart J 35 2014 1147 1158
32. D.E. Kandzari, M.B. Leon, J.J. Popma for the ENDEAVOR III Investigators Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial J Am Coll Cardiol 48 2006 2440 2447
33. M.B. Leon, L. Mauri, J.J. Popma for the ENDEAVOR IV Investigators A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial J Am Coll Cardiol 55 2010 543 554
34. S. Bangalore, B. Toklu, and N. Amoroso Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis BMJ 347 2013 f6625
35. Liu T, Lin W, Huang L, Chen S, Yang M. Surface characteristics and hemocompatibility of PAN/PVDF blend membranes Polym Adv Technol 2005;16:413-9.
36. K. Kolandaivelu, R. Swaminathan, and W.J. Gibson Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings Circulation 123 2011 1400 1409
37. Kereiakes DJ, Meredith IT, Windecker S, et al. Primary outcomes of the EVOLVE II Trial: a prospective randomized investigation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. Presented at: American Heart Association Scientific Sessions; November 24, 2014; Chicago, Illinois. Available at: http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm-469620.pdf. Accessed December 10, 2014.
38. T. Palmerini, U. Benedetto, and L. Bacchi-Reggiani Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomized trials Lancet 2015 Mar 13 [E-pub ahead of print]
39. M. Joner, G. Nakazawa, and A.V. Finn Endothelial cell recovery between comparator polymer-based drug-eluting stents J Am Coll Cardiol 52 2008 333 342
40. L.K. Pendyala, X. Yin, J. Li, J.P. Chen, N. Chronos, and D. Hou The first-generation drug-eluting stents and coronary endothelial dysfunction J Am Coll Cardiol Intv 2 2009 1169 1177
41. F. Otsuka, M. Vorpahl, and M. Nakano Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans Circulation 129 2014 211 223
42. M. Valgimigli, M. Sabaté, and C. Kaiser Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis BMJ 349 2014 g6427